Regeneron Pharmaceuticals acquires Checkmate Pharmaceuticals for $250 million, or $10.5 per share. The company is developing the drug vidutolimod based on proprietary technology to harness the power of the immune system in the fight against cancer. The deal is scheduled to close in mid-2022.